Osteonecrosis of the jaw in multiple myeloma patients (the IFM registry)

被引：0
|
作者：
Fuzibet, Jean Gabriel [1 ]
Viellard, Marie Helene [2 ]
Rossignol, Benoit B. R. [1 ]
Doyen, Chantal C. D. [3 ]
Hulin, Cyril [4 ]
Garderet, Laurent L. G. [5 ]
Blanc, Michel M. B. [6 ]
Marit, Gerald [7 ]
Facon, Thierry T. F. [8 ]
Moreau, Philippe [9 ]
机构：
[1] CHU Archet, Dept Internal Med, Nice, France
[2] CHRU Roger Salengro, Dept Rheumatol, Lille, France
[3] CU Mont Godinne, Dept Hematol, Yvoir, Belgium
[4] CHU Brabois, Dept Internal Med, Nancy, France
[5] CHU St Antoine, Dept Hematol, Paris, France
[6] Ctr Hosp, Dept Hematol, Chambery, France
[7] CHRU Haut Leveque, Dept Hematol, Pessac, France
[8] CHRU Claude Huriez, Lille, France
[9] CHRU, Hotel Dieu, Dept Hematol, Nantes, France
来源：
BLOOD | 2007年 / 110卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4809
引用
收藏
页码：276B / 276B
页数：1
相关论文
共 50 条
  • [21] Risk factors for bisphosphonate-related osteonecrosis of jaw in multiple myeloma patients
    Cafro, A. M.
    Babarano, L.
    Nichelatti, M.
    D'Avanzo, G.
    Gaglioti, D.
    Taroni, A.
    Riva, F.
    Nosari, A.
    Andriani, A.
    Morra, E.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 (06): : 215 - 216
  • [22] Jaw avascular osteonecrosis after treatment of multiple myeloma with zoledronate
    Lobato, J. V.
    Mauricio, A. C.
    Rodrigues, J. M.
    Cavaleiro, M. V.
    Cortez, P. P.
    Xavier, L.
    Botelho, C.
    Hussain, N. Sooraj
    Santos, J. D.
    JOURNAL OF PLASTIC RECONSTRUCTIVE AND AESTHETIC SURGERY, 2008, 61 (01): : 99 - 106
  • [23] Interruption of bisphosphonates (BP) therapy in multiple myeloma (MM) patients and osteonecrosis of the jaw (ONJ).
    Badros, Ashraf
    Goloubeva, Olga
    Weikel, Dianna
    Rapoport, Aaron P.
    Akpek, Gorgun
    Yanovich, Saul
    Meiller, Timothy
    Sausville, Edward
    BLOOD, 2006, 108 (11) : 345B - 345B
  • [24] Multiple Myeloma and IV Bisphosphonate Are Risk Factors for Osteonecrosis of the Jaw
    Tennis, Pat
    Rothman, Kenneth J.
    Bohn, Rhonda
    Tan, Hiangkat
    Anthony, Mary
    Zavras, Athanosios
    Calingaert, Brian
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2010, 19 : S313 - S314
  • [25] BISPHOSPHONATE-RELATED OSTEONECROSIS OF THE JAW IN PATIENTS WITH MULTIPLE MYELOMA: A SINGLE CENTRE EXPERIENCE
    Sagristani, M.
    Carola, A.
    Nasuti, A.
    Ferrigno, M.
    Vitiello, G.
    Battista, F.
    Mastrullo, L.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 543 - 543
  • [26] EPIDEMIOLOGY OF BISPHOSPHONATE USE AND JAW OSTEONECROSIS INCIDENCE IN MULTIPLE MYELOMA PATIENTS IN THE REPUBLIC OF IRELAND
    McHugh, J.
    Kumar, R. S.
    O'Dalaigh, A.
    Breen, K.
    McCloy, M.
    Rajpal, R.
    Burke, A.
    Kelly, M.
    Desmond, R.
    O'Rafferty, C.
    Hayden, P.
    Leahy, M.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 388 - 388
  • [27] Myeloma patients: genes increase risk for osteonecrosis of the jaw
    Becnel, Melody
    Manasanch, Elisabet Esteve
    LEUKEMIA & LYMPHOMA, 2017, 58 (10) : 2271 - 2272
  • [28] A different schedule of zoledronic acid can reduce the risk of the osteonecrosis of the jaw in patients with multiple myeloma
    Corso, A.
    Varettoni, M.
    Zappasodi, P.
    Klersy, C.
    Mangiacavalli, S.
    Pica, G.
    Lazzarino, M.
    LEUKEMIA, 2007, 21 (07) : 1545 - 1548
  • [29] Medication-related osteonecrosis of the jaw: a preliminary retrospective study of 130 patients with multiple myeloma
    Choi W.-S.
    Lee J.-I.
    Yoon H.-J.
    Min C.-K.
    Lee S.-H.
    Maxillofacial Plastic and Reconstructive Surgery, 39 (1)
  • [30] A different schedule of zoledronic acid can reduce the risk of the osteonecrosis of the jaw in patients with multiple myeloma
    A Corso
    M Varettoni
    P Zappasodi
    C Klersy
    S Mangiacavalli
    G Pica
    M Lazzarino
    Leukemia, 2007, 21 : 1545 - 1548
12345